

Steven Lentz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6647281/publications.pdf>

Version: 2024-02-01

201
papers

11,247
citations

23500

58
h-index

33814

99
g-index

202
all docs

202
docs citations

202
times ranked

11422
citing authors

#	ARTICLE	IF	CITATIONS
1	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 857-865.	1.9	14
2	Turoctocog alfa pegol (N8â€GP) in severe hemophilia A: Longâ€term safety and efficacy in previously treated patients of all ages in the pathfinder8 study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12674.	1.0	4
3	Myeloid Cell PKM2 Deletion Enhances Efferocytosis and Reduces Atherosclerosis. <i>Circulation Research</i> , 2022, 130, 1289-1305.	2.0	33
4	The metabolic enzyme pyruvate kinase M2 regulates platelet function and arterial thrombosis. <i>Blood</i> , 2021, 137, 1658-1668.	0.6	25
5	Smooth Muscle Cellâ€Specific PKM2 (Pyruvate Kinase Muscle 2) Promotes Smooth Muscle Cell Phenotypic Switching and Neointimal Hyperplasia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1724-1737.	1.1	19
6	Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cellâ€free DNA. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12557.	1.0	5
7	Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVIDâ€19: A multiâ€center, openâ€label, randomized controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2225-2234.	1.9	103
8	Cooling down VITT with IVIG. <i>Blood</i> , 2021, 138, 921-922.	0.6	7
9	Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1). <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 341-351.	1.9	15
10	Targeting Myeloid-Specific Integrin Î±9Î²1 Improves Short- and Long-Term Stroke Outcomes in Murine Models With Preexisting Comorbidities by Limiting Thrombosis and Inflammation. <i>Circulation Research</i> , 2020, 126, 1779-1794.	2.0	30
11	Pilot trial of semi-automated medical note writing using lexeme hypotheses. <i>International Journal of Medical Informatics</i> , 2020, 136, 104095.	1.6	0
12	Memantine Protects From Exacerbation of Ischemic Stroke and Blood Brain Barrier Disruption in Mild But Not Severe Hyperhomocysteinemia. <i>Journal of the American Heart Association</i> , 2020, 9, e013368.	1.6	14
13	Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials. <i>Haemophilia</i> , 2020, 26, 450-458.	1.0	11
14	Fixed doses of N8â€GP prophylaxis maintain moderateâ€toâ€mild factor VIII levels in the majority of patients with severe hemophilia A. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 542-554.	1.0	17
15	Longâ€term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to dâ€dimer results; A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1144-1152.	1.9	34
16	Is Homoarginine a Protective Cardiovascular Risk Factor?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 869-875.	1.1	37
17	Onceâ€weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8â€GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). <i>Haemophilia</i> , 2019, 25, 373-381.	1.0	29
18	Nox2 NADPH oxidase is dispensable for platelet activation or arterial thrombosis in mice. <i>Blood Advances</i> , 2019, 3, 1272-1284.	2.5	34

#	ARTICLE	IF	CITATIONS
19	Smooth muscle cell-specific fibronectin-EDA mediates phenotypic switching and neointimal hyperplasia. <i>Journal of Clinical Investigation</i> , 2019, 130, 295-314.	3.9	45
20	Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. <i>Blood</i> , 2018, 131, 2151-2160.	0.6	62
21	Fibronectin Containing Extra Domain A Induces Plaque Destabilization in the Innominate Artery of Aged Apolipoprotein E-deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 500-508.	1.1	18
22	The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 352-363.	1.9	21
23	Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. <i>Haemophilia</i> , 2018, 24, e391-e394.	1.0	15
24	Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9CGP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm, C trials. <i>Haemophilia</i> , 2018, 24, 911-920.	1.0	11
25	Helicopter Drip and Ship Flights Do Not Alter the Pharmacological Integrity of rtPA. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 2720-2724.	0.7	9
26	Haemophilia clinical care and research needs: Assessing priorities. <i>Haemophilia</i> , 2018, 24, e270-e273.	1.0	0
27	Targeting platelet EPCR for better therapeutic factor VIIa activity. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1814-1816.	1.9	0
28	Letter by Sonkar et al Regarding Article, "Class III PI3K Positively Regulates Platelet Activation and Thrombosis via PI(3)P-Directed Function of NADPH Oxidase". <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, e25.	1.1	1
29	Fibrin films: overlooked hemostatic barriers against microbial infiltration. <i>Journal of Clinical Investigation</i> , 2018, 128, 3243-3245.	3.9	7
30	Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program. <i>Blood</i> , 2018, 132, 979-979.	0.6	1
31	Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism. <i>Blood</i> , 2018, 132, 2506-2506.	0.6	6
32	ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1332-1338.	1.1	17
33	Clinical and laboratory phenotype variability in type 2M von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1559-1566.	1.9	13
34	Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1. <i>Cell Stem Cell</i> , 2017, 21, 359-373.e5.	5.2	40
35	Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1971-1976.	1.9	16
36	The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 224-229.	0.5	1

#	ARTICLE	IF	CITATIONS
37	On PAR with aPC to target inflammasomes. <i>Blood</i> , 2017, 130, 2579-2581.	0.6	1
38	Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. <i>Thrombosis and Haemostasis</i> , 2017, 117, 252-261.	1.8	96
39	Whole-exome sequencing in evaluation of patients with venous thromboembolism. <i>Blood Advances</i> , 2017, 1, 1224-1237.	2.5	55
40	Deficiency of superoxide dismutase promotes cerebral vascular hypertrophy and vascular dysfunction in hyperhomocysteinemia. <i>PLoS ONE</i> , 2017, 12, e0175732.	1.1	20
41	Dok-1 negatively regulates platelet integrin α IIb β 3 outside-in signalling and inhibits thrombosis in mice. <i>Thrombosis and Haemostasis</i> , 2016, 115, 969-978.	1.8	9
42	Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2016, 116, 42-49.	1.8	28
43	Genetic testing to guide warfarin dosing: Impact of direct oral anticoagulants. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 128-130.	2.3	5
44	Interim results from a large multinational extension trial (guardian ²) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. <i>Haemophilia</i> , 2016, 22, e445-9.	1.0	6
45	Thrombosis in the setting of obesity or inflammatory bowel disease. <i>Blood</i> , 2016, 128, 2388-2394.	0.6	47
46	Thrombosis in the setting of obesity or inflammatory bowel disease. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 180-187.	0.9	17
47	Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm ⁴). <i>Thrombosis Research</i> , 2016, 141, 69-76.	0.8	52
48	D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment. <i>Thrombosis Research</i> , 2016, 146, 119-125.	0.8	16
49	Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. <i>Blood</i> , 2016, 127, 2481-2488.	0.6	96
50	Von Willebrand Factor α 1 A Rapid Sensor of Paravalvular Regurgitation during TAVR?. <i>New England Journal of Medicine</i> , 2016, 375, 382-383.	13.9	3
51	Hypomorphic mutations in <i>TRNT1</i> cause retinitis pigmentosa with erythrocytic microcytosis. <i>Human Molecular Genetics</i> , 2016, 25, 44-56.	1.4	64
52	Protein methionine oxidation augments reperfusion injury in acute ischemic stroke. <i>JCI Insight</i> , 2016, 1, .	2.3	30
53	the NADPH Oxidase Catalytic Subunit Nox2 Displays Differential Roles in Arterial Vs. Venous Thrombosis. <i>Blood</i> , 2016, 128, 4907-4907.	0.6	0
54	Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight [®]) in previously treated patients with severe haemophilia A: interim results of the guardian ² extension trial. <i>Haemophilia</i> , 2015, 21, e436-9.	1.0	10

#	ARTICLE	IF	CITATIONS
55	Cellular fibronectin containing extra domain A promotes arterial thrombosis in mice through platelet Toll-like receptor 4. <i>Blood</i> , 2015, 125, 3164-3172.	0.6	59
56	Regulation of thrombosis and vascular function by protein methionine oxidation. <i>Blood</i> , 2015, 125, 3851-3859.	0.6	53
57	Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1989-1998.	1.9	54
58	Endothelial PPAR- δ Protects Against Vascular Thrombosis by Downregulating P-Selectin Expression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 838-844.	1.1	33
59	Case report: paroxysmal cold hemoglobinuria presenting during pregnancy. <i>BMC Hematology</i> , 2015, 15, 3.	2.6	4
60	Fibronectin Splicing Variants Containing Extra Domain A Promote Atherosclerosis in Mice Through Toll-Like Receptor 4. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2391-2400.	1.1	51
61	Deficiency of Superoxide Dismutase Impairs Protein C Activation and Enhances Susceptibility to Experimental Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1798-1804.	1.1	21
62	Genetic Ablation of Extra Domain A of Fibronectin in Hypercholesterolemic Mice Improves Stroke Outcome by Reducing Thrombo-Inflammation. <i>Circulation</i> , 2015, 132, 2237-2247.	1.6	38
63	Deletion of Methionine Sulfoxide Reductase A Does Not Affect Atherothrombosis but Promotes Neointimal Hyperplasia and Extracellular Signal-Regulated Kinase 1/2 Signaling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2594-2604.	1.1	10
64	D-Dimer Testing to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Stop Anticoagulant Therapy. <i>Annals of Internal Medicine</i> , 2015, 162, 27-34.	2.0	128
65	Safety and efficacy of turoctocog alfa (NovoEight [®]) during surgery in patients with haemophilia A: results from the multinational guardian [®] clinical trials. <i>Haemophilia</i> , 2015, 21, 34-40.	1.0	40
66	Protective Vascular and Cardiac Effects of Inducible Nitric Oxide Synthase in Mice with Hyperhomocysteinemia. <i>PLoS ONE</i> , 2014, 9, e107734.	1.1	17
67	Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1244-1253.	1.9	61
68	A novel supplemental approach to capturing post-marketing safety information on recombinant factor VIIa in acquired hemophilia: the Acquired Hemophilia Surveillance project. <i>Journal of Blood Medicine</i> , 2014, 5, 1.	0.7	6
69	Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. <i>Haemophilia</i> , 2014, 20, 527-534.	1.0	42
70	AGXT2: a promiscuous aminotransferase. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 575-582.	4.0	57
71	Turoctocog alfa and drug development for hemophilia A. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 419-431.	0.5	2
72	Factor VIII Dosing and Preventive Efficacy in Obese Patients with Hemophilia (BMI ≥ 30 kg/m ²) – a Post-Hoc Sub-Analysis of the guardian [®] Trials. <i>Blood</i> , 2014, 124, 1503-1503.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Safety and Efficacy of Nonacog Beta Pegol (N9-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously-Treated Patients with Hemophilia B: Results from an Extension Trial. <i>Blood</i> , 2014, 124, 2846-2846.	0.6	2
74	Results from a large multinational clinical trial (guardianâ„†1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia <sc>A</sc>: safety and efficacy. <i>Haemophilia</i> , 2013, 19, 691-697.	1.0	81
75	Dominant negative PPAR ^{Î³} promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2013, 304, R690-R701.	0.9	35
76	Mechanisms of thrombosis in obesity. <i>Current Opinion in Hematology</i> , 2013, 20, 437-444.	1.2	221
77	Trends in clinical laboratory homocysteine testing from 1997 to 2010: the impact of evidence on clinical practice at a single institution. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 671-5.	1.4	0
78	Hydrogen Peroxide Promotes Aging-Related Platelet Hyperactivation and Thrombosis. <i>Circulation</i> , 2013, 127, 1308-1316.	1.6	150
79	Comparison of clotâ€based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1300-1309.	1.9	56
80	Enhancing the pharmacokinetic properties of recombinant factorâˆVIII: first-in-human trial of glycoPEGylated recombinant factorâˆVIII in patients with hemophiliaâˆA. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 670-678.	1.9	150
81	Dissecting The Effects Of Isoprenoid Pathway Inhibition On Hemostasis and Thrombosis: Differential Effects Of Atorvastatin and Digeranyl Bisphosphonate In Hypercholesterolemic Mice. <i>Blood</i> , 2013, 122, 2378-2378.	0.6	0
82	Alternatively-Spliced Extra Domain A of Fibronectin Promotes Acute Inflammation and Brain Injury After Cerebral Ischemia in Mice. <i>Stroke</i> , 2012, 43, 1376-1382.	1.0	61
83	ADAMTS13 deficiency exacerbates VWF-dependent acute myocardial ischemia/reperfusion injury in mice. <i>Blood</i> , 2012, 120, 5224-5230.	0.6	85
84	ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. <i>Blood</i> , 2012, 119, 2385-2391.	0.6	97
85	ADAMTS13 reduces VWFâ€mediated acute inflammation following focal cerebral ischemia in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1665-1671.	1.9	75
86	Paradoxical absence of a prothrombotic phenotype in a mouse model of severe hyperhomocysteinemia. <i>Blood</i> , 2012, 119, 3176-3183.	0.6	32
87	Recombinant factorâˆVIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 81-89.	1.9	33
88	Critical von Willebrand factor A1 domain residues influence type VI collagen binding. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1417-1424.	1.9	54
89	Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardianâ„† Trials.. <i>Blood</i> , 2012, 120, 2228-2228.	0.6	1
90	ADAMTS13 Deficiency Exacerbates VWF-Dependent Acute Myocardial Ischemia/Reperfusion Injury in Mice. <i>Blood</i> , 2012, 120, 264-264.	0.6	2

#	ARTICLE	IF	CITATIONS
91	A Novel Approach to Capturing Post-Marketing Safety Information On Recombinant Factor VIIa (rFVIIa) in Acquired Hemophilia: Final Data From the Acquired Hemophilia Surveillance (AHS) Project. <i>Blood</i> , 2012, 120, 3371-3371.	0.6	1
92	ADAMTS13 Reduces Vascular Inflammation and Early Development of Atherosclerosis Via VWF-Dependent Mechanism.. <i>Blood</i> , 2012, 120, 2178-2178.	0.6	0
93	Durable responses to rituximab in acquired factor VIII deficiency. <i>Thrombosis and Haemostasis</i> , 2011, 106, 172-174.	1.8	10
94	Human Thrombomodulin Knock-In Mice Reveal Differential Effects of Human Thrombomodulin on Thrombosis and Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2509-2517.	1.1	11
95	Epigenetic regulation of hepatic endoplasmic reticulum stress pathways in the ethanol-fed cystathionine beta synthase-deficient mouse. <i>Hepatology</i> , 2010, 51, 932-941.	3.6	72
96	The Nutrigenetics of Hyperhomocysteinemia. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 471-485.	2.5	22
97	Overexpression of Dimethylarginine Dimethylaminohydrolase Protects Against Cerebral Vascular Effects of Hyperhomocysteinemia. <i>Circulation Research</i> , 2010, 106, 551-558.	2.0	39
98	Human Alanine-Glyoxylate Aminotransferase 2 Lowers Asymmetric Dimethylarginine and Protects from Inhibition of Nitric Oxide Production. <i>Journal of Biological Chemistry</i> , 2010, 285, 5385-5391.	1.6	94
99	The Acquired Hemophilia Surveillance (AHS) Project: A Novel Mechanism of Capturing Post-Marketing Safety Information on rFVIIa (NovoSeven®RT) In Acquired Hemophilia.. <i>Blood</i> , 2010, 116, 3674-3674.	0.6	0
100	Durable Responses to Rituximab In Acquired Factor VIII Deficiency.. <i>Blood</i> , 2010, 116, 3680-3680.	0.6	0
101	EDA-Containing Fibronectin Aggravates Ischemic Brain Injury In Mice. <i>Blood</i> , 2010, 116, 330-330.	0.6	0
102	Countervailing Effects on Atherogenesis and Plaque Stability. <i>Circulation</i> , 2009, 120, 722-724.	1.6	2
103	Role of Hydrogen Peroxide and the Impact of Glutathione Peroxidase-1 in Regulation of Cerebral Vascular Tone. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1130-1137.	2.4	30
104	Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. <i>Blood</i> , 2009, 114, 1666-1674.	0.6	95
105	Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. <i>Blood</i> , 2008, 111, 1257-1265.	0.6	189
106	Glutathione Peroxidase-1 Plays a Major Role in Protecting Against Angiotensin II-Induced Vascular Dysfunction. <i>Hypertension</i> , 2008, 51, 872-877.	1.3	79
107	Murine Models of Hyperhomocysteinemia and Their Vascular Phenotypes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1596-1605.	1.1	100
108	Overexpression of Dimethylarginine Dimethylaminohydrolase Inhibits Asymmetric Dimethylarginine-Induced Endothelial Dysfunction in the Cerebral Circulation. <i>Stroke</i> , 2008, 39, 180-184.	1.0	78

#	ARTICLE	IF	CITATIONS
109	The Homocysteine Paradox. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1031-1033.	1.1	33
110	Many Potential Explanations for the Homocysteine Paradox. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, .	1.1	1
111	Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H816-H825.	1.5	52
112	The emerging role of asymmetric dimethylarginine in cardiovascular disease. <i>Arterial Hypertension (Russian Federation)</i> , 2008, 14, 306-314.	0.1	3
113	Hypermethylation of Fads2 and Altered Hepatic Fatty Acid and Phospholipid Metabolism in Mice with Hyperhomocysteinemia. <i>Journal of Biological Chemistry</i> , 2007, 282, 37082-37090.	1.6	70
114	Testosterone regulation of renal cystathionine Î²-synthase: implications for sex-dependent differences in plasma homocysteine levels. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F594-F600.	1.3	47
115	Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 175-181.	1.1	78
116	Cerebral Vascular Dysfunction During Hypercholesterolemia. <i>Stroke</i> , 2007, 38, 2136-2141.	1.0	85
117	Protein Phosphatase 2A Methyltransferase Links Homocysteine Metabolism with Tau and Amyloid Precursor Protein Regulation. <i>Journal of Neuroscience</i> , 2007, 27, 2751-2759.	1.7	216
118	Prothrombotic Effects of Hyperhomocysteinemia and Hypercholesterolemia in ApoE-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 233-240.	1.1	43
119	Role of Redox Reactions in the Vascular Phenotype of Hyperhomocysteinemic Animals. <i>Antioxidants and Redox Signaling</i> , 2007, 9, 1899-1910.	2.5	24
120	Genetic Evidence that Cerebrovascular Responses to Arachidonic Acid are Mediated by Hydrogen Peroxide Produced by SODâ€¹. <i>FASEB Journal</i> , 2007, 21, A1384.	0.2	0
121	Hyperhomocysteinemia increases arterial permeability and stiffness in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006, 291, R1349-R1354.	0.9	13
122	A novel ELISA for mouse activated protein C in plasma. <i>Journal of Immunological Methods</i> , 2006, 314, 174-181.	0.6	16
123	Influence of Folate on Arterial Permeability and Stiffness in the Absence or Presence of Hyperhomocysteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 814-818.	1.1	25
124	ApoA-I. <i>Circulation Research</i> , 2006, 98, 431-433.	2.0	27
125	Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. <i>Blood</i> , 2006, 108, 2237-2243.	0.6	85
126	Overexpression of DDAHâ€¹ in mice inhibits effects of ADMA on endothelial function in the cerebral circulation.. <i>FASEB Journal</i> , 2006, 20, A731.	0.2	0

#	ARTICLE	IF	CITATIONS
127	Changes in Liver Fads2 expression and Phospholipid Fatty Acids in Mice with Hyperhomocysteinemia. FASEB Journal, 2006, 20, .	0.2	0
128	Another Lesson From the Factor V Leiden Mouse. Circulation, 2005, 111, 1733-1734.	1.6	10
129	Role of FcR ^β and factor XIIIa in coated platelet formation. Blood, 2005, 106, 4146-4151.	0.6	43
130	Mechanisms of homocysteine-induced atherothrombosis. Journal of Thrombosis and Haemostasis, 2005, 3, 1646-1654.	1.9	309
131	The benefits of excess EPCR. Journal of Thrombosis and Haemostasis, 2005, 3, 1349-1350.	1.9	4
132	ADMA and hyperhomocysteinemia. Vascular Medicine, 2005, 10, S27-S33.	0.8	53
133	Mechanisms of the Atherogenic Effects of Elevated Homocysteine in Experimental Models. Seminars in Vascular Medicine, 2005, 5, 163-171.	2.1	29
134	Tissue-specific Changes in H19 Methylation and Expression in Mice with Hyperhomocysteinemia. Journal of Biological Chemistry, 2005, 280, 25506-25511.	1.6	84
135	ADMA and hyperhomocysteinemia. Vascular Medicine, 2005, 10, S27-S33.	0.8	62
136	Cerebral Vascular Dysfunction in Methionine Synthase ^{-/-} Deficient Mice. Circulation, 2005, 112, 737-744.	1.6	60
137	TNF Family Protein Regulation in Megakaryocytes and Platelets.. Blood, 2005, 106, 4250-4250.	0.6	0
138	Association of Multiple Cellular Stress Pathways With Accelerated Atherosclerosis in Hyperhomocysteinemic Apolipoprotein E-Deficient Mice. Circulation, 2004, 110, 207-213.	1.6	193
139	Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 287, R39-R46.	0.9	96
140	Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death and Differentiation, 2004, 11, S56-S64.	5.0	334
141	Expression of TNF-related apoptosis-inducing ligand (TRAIL) in megakaryocytes and platelets. Experimental Hematology, 2004, 32, 1073-1081.	0.2	38
142	Hyperhomocysteinemia, Oxidative Stress, and Cerebral Vascular Dysfunction. Stroke, 2004, 35, 345-347.	1.0	204
143	Cerebral Vascular Dysfunction Mediated by Superoxide in Hyperhomocysteinemic Mice. Stroke, 2004, 35, 1957-1962.	1.0	146
144	Effect of Mthfr genotype on diet-induced hyperhomocysteinemia and vascular function in mice. Blood, 2004, 103, 2624-2629.	0.6	100

#	ARTICLE	IF	CITATIONS
145	Cerebral Vascular Dysfunction in Methionine Synthase-Deficient Mice.. Blood, 2004, 104, 2617-2617.	0.6	3
146	Homocysteine: is it a clinically important cardiovascular risk factor?. Cleveland Clinic Journal of Medicine, 2004, 71, 729-734.	0.6	91
147	Hyperhomocysteinemic Mice Have Increased Susceptibility to Carotid Artery Thrombosis.. Blood, 2004, 104, 2616-2616.	0.6	2
148	Effect of mechanical ventilation on carotid artery thrombosis induced by photochemical injury in mice. Journal of Thrombosis and Haemostasis, 2003, 1, 2669-2674.	1.9	28
149	Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atherosclerosis Supplements, 2003, 4, 61-65.	1.2	95
150	Platelet-Mediated Modulation of Adaptive Immunity. Immunity, 2003, 19, 9-19.	6.6	353
151	Thrombosis of Vein Grafts. Circulation Research, 2003, 92, 12-13.	2.0	100
152	Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood, 2003, 102, 146-151.	0.6	72
153	ATVB In Focus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1064-1064.	1.1	0
154	Structure of Cerebral Arterioles in Cystathionine Î²-Synthase-Deficient Mice. Circulation Research, 2002, 91, 931-937.	2.0	65
155	Deficiency of Glutathione Peroxidase-1 Sensitizes Hyperhomocysteinemic Mice to Endothelial Dysfunction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1996-2002.	1.1	99
156	Anticoagulant Responses to Thrombin Are Enhanced During Regression of Atherosclerosis in Monkeys. Circulation, 2002, 106, 842-846.	1.6	22
157	Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen. Blood, 2002, 100, 2839-2844.	0.6	22
158	Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factorâ€™s cleaving protease activity. Blood, 2002, 99, 437-442.	0.6	60
159	Effect of hyperhomocysteinemia on protein C activation and activity. Blood, 2002, 100, 2108-2112.	0.6	36
160	Prothrombotic states that predispose to stroke. Current Treatment Options in Neurology, 2002, 4, 417-425.	0.7	17
161	Does Homocysteine Promote Atherosclerosis?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1385-1386.	1.1	34
162	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clinical Science, 2001, 100, 161-167.	1.8	166

#	ARTICLE	IF	CITATIONS
163	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. <i>Clinical Science</i> , 2001, 100, 161.	1.8	70
164	Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. <i>Journal of Clinical Investigation</i> , 2001, 107, 1263-1273.	3.9	619
165	Endothelial Dysfunction and Elevation of <i>S</i> -Adenosylhomocysteine in Cystathionine β -Synthase-Deficient Mice. <i>Circulation Research</i> , 2001, 88, 1203-1209.	2.0	202
166	Supplementation of Atherogenic Diet With B Vitamins Does Not Prevent Atherosclerosis or Vascular Dysfunction in Monkeys. <i>Circulation</i> , 2001, 103, 1006-1011.	1.6	37
167	Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. <i>Clinical Science</i> , 2001, 100, 161-7.	1.8	35
168	Folate dependence of hyperhomocysteinemia and vascular dysfunction in cystathionine β -synthase-deficient mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 279, H970-H975.	1.5	89
169	Electronic Communication at Arteriosclerosis, Thrombosis, and Vascular Biology. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1851-1851.	1.1	0
170	Homocysteine and Its Disulfide Derivatives. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1704-1706.	1.1	204
171	Plasma Concentration of Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Is Elevated in Monkeys With Hyperhomocyst(e)inemia or Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1557-1564.	1.1	249
172	Impaired Anticoagulant Response to Infusion of Thrombin in Atherosclerotic Monkeys Associated With Acquired Defects in the Protein C System. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1744-1750.	1.1	30
173	Expression of Thrombomodulin and Consequences of Thrombomodulin Deficiency during Healing of Cutaneous Wounds. <i>American Journal of Pathology</i> , 1999, 155, 1569-1575.	1.9	23
174	Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. <i>Journal of Clinical Investigation</i> , 1999, 103, 19-25.	3.9	157
175	Remission after 13-cis retinoic acid in thrombotic thrombocytopenic purpura. <i>Lancet</i> , The, 1998, 352, 454-455.	6.3	25
176	Mechanisms of thrombosis in hyperhomocysteinemia. <i>Current Opinion in Hematology</i> , 1998, 5, 343-349.	1.2	59
177	Keratinocyte-specific expression of human thrombomodulin in transgenic mice: effects on epidermal differentiation and cutaneous wound healing. <i>Journal of Investigative Medicine</i> , 1998, 46, 127-33.	0.7	12
178	HOMOCYSTEINE AND VASCULAR DYSFUNCTION. <i>Life Sciences</i> , 1997, 61, 1205-1215.	2.0	115
179	Consequences of Hyperhomocyst(e)inemia on Vascular Function in Atherosclerotic Monkeys. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2930-2934.	1.1	67
180	Functional Interactions Between the Thrombin Receptor and the T-Cell Antigen Receptor in Human T-Cell Lines. <i>Blood</i> , 1997, 90, 1893-1901.	0.6	22

#	ARTICLE	IF	CITATIONS
181	Atherosclerotic vascular disease: will folate or gene therapy be useful?. Transactions of the American Clinical and Climatological Association, 1997, 108, 69-76; discussion 76-7.	0.9	0
182	INTERFERENCE IN PROTEIN C ACTIVATION ASSAYS FROM ENDOGENOUS SERPINS IN MAMMALIAN HOST CELLS. Thrombosis Research, 1996, 84, 373-377.	0.8	0
183	Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia.. Journal of Clinical Investigation, 1996, 98, 24-29.	3.9	463
184	Regulation of thrombomodulin expression by all-trans retinoic acid and tumor necrosis factor-alpha: differential responses in keratinocytes and endothelial cells. Blood, 1996, 88, 2043-9.	0.6	4
185	Cellular localization of thrombomodulin in human epithelium and squamous malignancies. American Journal of Pathology, 1995, 146, 933-43.	1.9	25
186	Thrombomodulin expression by human keratinocytes. Induction of cofactor activity during epidermal differentiation.. Journal of Clinical Investigation, 1994, 93, 1846-1851.	3.9	68
187	Recurrent neuroendocrine (merkel cell) carcinoma of the skin presenting as marrow failure in a man with systemic lupus erythematosus. Medical and Pediatric Oncology, 1993, 21, 137-141.	1.0	24
188	Structure-Function Relationships of the Thrombin-Thrombomodulin Interaction. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1993, 23, 183-193.	0.5	22
189	Sequences required for thrombomodulin cofactor activity within the fourth epidermal growth factor-like domain of human thrombomodulin. Journal of Biological Chemistry, 1993, 268, 15312-7.	1.6	18
190	Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood, 1993, 81, 683-9.	0.6	24
191	Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. Journal of Biological Chemistry, 1992, 267, 6164-70.	1.6	68
192	Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 6775-6779.	3.3	131
193	Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.. Journal of Clinical Investigation, 1991, 88, 1906-1914.	3.9	402
194	Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood, 1991, 77, 542-50.	0.6	39
195	Squamous cell carcinoma in epidermolysis bullosa. Treatment with systemic chemotherapy. Cancer, 1990, 66, 1276-1278.	2.0	33
196	Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogs. Biochemistry, 1990, 29, 10602-10612.	1.2	93
197	Posttranslational modification of the carboxy-terminal region of the .beta. subunit of human chorionic gonadotropin. Biochemistry, 1984, 23, 5330-5337.	1.2	11
198	Effects of 1,2-dimethoxyethane on the catalytic and coenzyme properties of glycogen phosphorylase. Biochemistry, 1981, 20, 2537-2544.	1.2	20

#	ARTICLE	IF	CITATIONS
199	Malate dehydrogenase: Isolation from E. coli and comparison with the eukaryotic mitochondrial and cytoplasmic forms. Bioscience Reports, 1981, 1, 497-507.	1.1	28
200	Bleeding from Acquired Coagulation Defects and Antithrombotic Therapy. , 0, , 376-390.		3
201	Standard Prophylactic Versus Intermediate Dose Enoxaparin in Adults with Severe COVID-19: A Multi-Center, Open-Label, Randomised Controlled Trial. SSRN Electronic Journal, 0, , .	0.4	2